Propranolol as antiangiogenic candidate for the therapy of hereditary haemorrhagic telangiectasia

Thrombosis and Haemostasis

Volumn 108, Issue 1, 2012, Pages 41-53

  Albiñana, Virginia ^a   Recio Poveda, Lucía ^a   Zarrabeitia, Roberto ^b   Bernabéu, Carmelo ^a   Botella, Luisa María ^a  

^a CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^b HOSPITAL SIERRALLANA   (Spain)

Author keywords

ALK1; Endoglin; Epistaxis; HHT; Propranolol

Indexed keywords

ACTIVIN RECEPTOR LIKE KINASE 1; CASPASE 3; ENDOGLIN; GELATINASE A; GELATINASE B; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROCASPASE 3; PROPRANOLOL; TRANSFORMING GROWTH FACTOR BETA; UROKINASE;

ANIMAL CELL; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CHROMATIN CONDENSATION; CONTROLLED STUDY; ENDOTHELIUM CELL; FIBRINOLYSIS; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RENDU OSLER WEBER DISEASE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; WOUND HEALING; ZYMOGRAPHY;

ACTIVIN RECEPTORS, TYPE II; ADRENERGIC BETA-ANTAGONISTS; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIGENS, CD; APOPTOSIS; CELL LINE; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; HUMANS; MICE; MICE, KNOCKOUT; MUTATION; NEOVASCULARIZATION, PATHOLOGIC; PROPRANOLOL; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION; TELANGIECTASIA, HEREDITARY HEMORRHAGIC;

EID: 84863709689     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH11-11-0809     Document Type: Article

References (42)

1. Black JW, Duncan WA, Shanks RG. Comparison of some properties of pronethalol and Propranolol. Br J Pharmacol Chemother 1965; 25: 577-591.
2. Zimmermann AP, Wiegand S, Werner JA, et al. Propranolol therapy for infantile haemangiomas: review of the literature. Int J Pediatr Otorhinolaryngol 2010; 74: 338-342.
3. Sanchez-Perez RS, Mora PC, Rodriguez JD, et al. Treatment of infantile hemangioma with Propranolol. An Pediatr (Barc) 2009; 72: 152-154.
4. Sanchez-Carpintero I, Ruiz-Rodriguez R, Lopez-Gutierrez JC. Propranolol in the treatment of infantile hemangioma: clinical effectiveness, risks, and recommendations. Actas dermosifiliogr 2011; 102: 766-779.
5. Leaute-Labreze C, Dumas de la Roque E, Hubiche T, et al. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008; 358: 2649-2651.
6. Storch CH, Hoeger PH. Propranolol for infantile haemangiomas: insights into the molecular mechanisms of action. Br J Dermatol 2010; 163: 269-274.
7. Lamy S, Lachambre MP, Lord-Dufour S, et al. Propranolol suppresses angiogenesis in vitro: inhibition of proliferation, migration, and differentiation of endothelial cells. Vascul Pharmacol 2010; 53: 200-208.
8. Annabi B, Lachambre MP, Plouffe K, et al. Propranolol adrenergic blockade inhibits human brain endothelial cells tubulogenesis and matrix metalloproteinase- 9 secretion. Pharmacol Res 2009; 60: 438-445.
9. Sommers-Smith. Beta blockade induces apoptosis in cultured capillary endothelial cells. In Vitro Cell Dev Biol Anim 2002; 38: 298-304.
10. Shovlin CL, Letarte M. Hereditary haemorrhagic telangiectasia and pulmonary arteriovenous malformations: issues in clinical management and review of pathogenic mechanisms. Thorax 1999; 54: 714-729.
11. Govani FS, Shovlin CL. Hereditary haemorrhagic telangiectasia: a clinical and scientific review. Eur J Hum Genet 2009; 17: 860-871.
12. Johnson DW, Berg JN, Baldwin MA, et al. Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet 1996; 13: 189-195.
13. McAllister KA, Grogg KM, Johnson DW, et al. Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 1994; 8: 345-351.
14. Gallione CJ, Repetto GM, Legius E, et al. A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4). Lancet 2004; 363: 852-859.
15. Gallione CJ, Richards JA, Letteboer TG, et al. SMAD4 mutations found in unselected HHT patients. J Med Genet 2006; 43: 793-797.
16. Shovlin CL. Hereditary haemorrhagic telangiectasia: pathophysiology, diagnosis and treatment. Blood Rev 2010; 24: 203-219.
17. Morales-Angulo C, del Valle-Zapico A. Hereditary hemorrhagic telangiectasia. Otolaryngol Head Neck Surg 1998; 119: 293.
18. Plauchu H, de Chadarevian JP, Bideau A, et al. Age-related clinical profile of hereditary hemorrhagic telangiectasia in an epidemiologically recruited population. Am J Med Genet 1989; 32: 291-297.
19. Zarrabeitia R, Albiñana V, Salcedo M, et al. A review on clinical management and pharmacological therapy on hereditary haemorrhagic telangiectasia (HHT). Curr Vasc Pharmacol 2010; 8: 473-481.
20. Fernandez LA, Garrido-Martin EM, Sanz-Rodriguez F, et al. Therapeutic action of tranexamic acid in hereditary haemorrhagic telangiectasia (HHT): regulation of ALK-1/endoglin pathway in endothelial cells. Thromb Haemost 2007; 97: 254-262.
21. Morales-Angulo C, Perez del Molino A, Zarrabeitia R, et al. Treatment of epistaxes in hereditary haemorrhagic telangiectasia (Rendu-Osler-Weber disease) with tranexamic acid. Acta Otorrinolaringol Esp 2007; 58: 129-132.
22. de Gussem EM, Snijder RJ, Disch FJ, et al. The effect of N-acetylcysteine on epistaxis and quality of life in patients with HHT: a pilot study. Rhinology 2009; 47: 85-88.
23. Albiñana V, Bernabeu-Herrero ME, Zarrabeitia R, et al. Estrogen therapy for hereditary haemorrhagic telangiectasia (HHT): Effects of raloxifene, on Endoglin and ALK1 expression in endothelial cells. Thromb Haemost 2010; 103: 525-534.
24. Patrizia S, Arcangelo L, Carlo S. Low dose intravenous bevacizumab for the treatment of anaemia in hereditary haemorrhagic telangiectasia. Br J Haematol 2011; 152: 365.
25. Lebrin F, Srun S, Raymond K, et al. Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia. Nat Med 2010; 16: 420-428.
26. Ades EW, Candal FJ, Swerlick RA, et al. HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J Invest Dermatol 1992; 99: 683-690.
27. Hoak JC, Warner ED, Cheng HF, et al. Hemangioma with thrombocytopenia and microangiopathic anemia (Kasabach-Merritt syndrome): an animal model. J Lab Clin Med 1971; 77: 941-950.
28. Albiñana V, Sanz-Rodriguez F, Recio-Poveda L, et al. Immunosuppressor FK506 increases endoglin and activin receptor-like kinase 1 expression and modulates transforming growth factor-beta1 signaling in endothelial cells. Mol Pharmacol 2011; 79: 833-843.
29. Sanchez-Elsner T, Botella LM, Velasco B, et al. Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-beta pathways. J Biol Chem 2002; 277: 43799-43808.
30. Garrido-Martin EM, Blanco FJ, Fernandez LA, et al. Characterization of the human Activin-A receptor type II-like kinase 1 (ACVRL1) promoter and its regulation by Sp1. BMC Mol Biol 2010; 11: 51.
31. Suzuki Y, Shimada J, Shudo K, et al. Physical interaction between retinoic acid receptor and Sp1: mechanism for induction of urokinase by retinoic acid. Blood 1999; 93: 4264-4276.
32. van Zonneveld AJ, Curriden SA, Loskutoff DJ. Type 1 plasminogen activator inhibitor gene: functional analysis and glucocorticoid regulation of its promoter. Proc Natl Acad Sci USA 1988; 85: 5525-5529.
33. Goumans MJ, Valdimarsdottir G, Itoh S, et al. Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. EMBO J 2002; 21: 1743-1753.
34. Peracchia F, Polentarutti N, Colotta F, et al. Increased expression of urokinase mRNA in bovine aortic endothelial cells treated with Propranolol. Biochem Biophys Res Commun 1989; 160: 977-981.
35. Sabba C, Gallitelli M, Palasciano G. Efficacy of unusually high doses of tranexamic acid for the treatment of epistaxis in hereditary hemorrhagic telangiectasia. N Engl J Med 2001; 345: 926.
36. Kwaan HC, Silverman S. Fibrinolytic activity in lesions of hereditary hemorrhagic telangiectasia. Arch Dermatol 1973; 107: 571-573.
37. Lebrin F, Goumans MJ, Jonker L, et al. Endoglin promotes endothelial cell proliferation and TGF-beta/ALK1 signal transduction. EMBO J. 2004; 23: 4018-4028.
38. Fodstad P, Dheyauldeen S, Rinde M, et al. Anti-VEGF with 3-week intervals is effective on anemia in a patient with severe hereditary hemorrhagic telangiectasia. Ann Hematol 2011; 90: 611-612.
39. Gialeli C, Theocharis AD, Karamanos NK. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 2010; 278: 16-27.
40. Olitsky SE. Topical timolol for the treatment of epistaxis in hereditary hemorrhagic telangiectasia. Am J Otolaryngol 2011; epub ahead of print.
41. Brommer EJ, Derkx FH, Barrett-Bergshoeff MM, et al. The inability of propranolol and aspirin to inhibit the response of fibrinolytic activity and factor VIIIantigen to infusion of DDAVP. Thromb Haemost 1984; 51: 42-44.
42. Schönauer V, Giannini S, Christ G, et al. The effect of beta-receptor blockade on factor VIII levels and thrombin generation in patients with venous thromboembolism. Thromb Haemost 2003; 89: 837-841.